Stuart Felzer, MD
Internal Medicine · Wilmington, DENPI 1508804402
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.5% of the total across 327 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 13.1% — the pattern of someone who eats at a lot of different presentations. Among internal medicine clinicians in DE with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 327 payments — averaging $17.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$768
- AstraZeneca$766
- Lilly USA, LLC$713
- Pfizer$652
- Astellas Pharma US Inc$537
- AbbVie$332
- plus $2K from 25 others
What the payments were for
- Food & beverage$5,61196%
- Education$2624%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 39 | $768 |
| AstraZeneca | 44 | $766 |
| Lilly USA, LLC | 36 | $713 |
| Pfizer | 42 | $652 |
| Astellas Pharma US Inc | 23 | $537 |
| AbbVie(2 entities) | 21 | $332 |
| Boehringer Ingelheim | 17 | $323 |
| GSK | 11 | $203 |
| Amarin Pharma, Inc. | 12 | $188 |
| Sumitomo Pharma America, Inc. | 9 | $183 |
| Merck | 11 | $161 |
| Sanofi-aventis U.S. LLC | 8 | $155 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $136 |
| Johnson & Johnson | 7 | $111 |
| Abbott | 6 | $109 |
| Amgen | 7 | $102 |
| Bausch Health US, LLC | 5 | $73 |
| Teva Pharmaceuticals USA, Inc. | 3 | $47 |
| Eisai Inc. | 3 | $43 |
| Tactile Systems Technology Inc | 1 | $38 |
| Seqirus USA Inc | 2 | $37 |
| Kowa Pharmaceuticals America, Inc. | 3 | $36 |
| Antares Pharma, Inc. | 1 | $26 |
| Medtronic | 1 | $25 |
| Collegium Pharmaceutical, Inc. | 1 | $19 |
| Idorsia Pharmaceuticals US Inc | 1 | $19 |
| Scilex Pharmaceuticals Inc. | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Alfasigma USA, Inc. | 1 | $13 |
| Sanofi Pasteur Inc. | 1 | $12 |
How this compares
$5,874 in reported general payments places this provider in the 90th percentile of 477 internal medicine providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 91 | $97,188 |
| OzempicSemaglutide | 38 | $75,338 |
| FarxigaDapagliflozin Propanediol | 67 | $74,619 |
| JardianceEmpagliflozin | 45 | $53,404 |
| XareltoRivaroxaban | 27 | $45,419 |
| JanuviaSitagliptin Phosphate | 44 | $43,654 |
| MyrbetriqMirabegron | 35 | $35,096 |
| RybelsusSemaglutide | 13 | $30,965 |
| CreonLipase/Protease/Amylase | 13 | $29,697 |
| Tresiba Flextouch U-200Insulin Degludec | 19 | $27,451 |
| VascepaIcosapent Ethyl | 51 | $23,428 |
| TradjentaLinagliptin | 16 | $22,909 |
| Tresiba Flextouch U-100Insulin Degludec | 22 | $21,912 |
| MounjaroTirzepatide | 21 | $21,187 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $20,178 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $768 | $106,30351 claims |
| PfizerEliquis | $652 | $97,18891 claims |
| Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat | $323 | $87,73372 claims |
| AstraZenecaFarxiga, Symbicort | $766 | $78,24880 claims |
| Johnson & JohnsonXarelto | $111 | $45,41927 claims |
| MerckJanuvia | $161 | $43,65444 claims |
| AbbVieCreon, Synthroid | $332 | $39,296157 claims |
| Lilly USA, LLCMounjaro, Trulicity | $713 | $35,56733 claims |
| Astellas Pharma US IncMyrbetriq | $537 | $35,09635 claims |
| GSKTrelegy Ellipta | $203 | $18,60916 claims |
| Collegium Pharmaceutical, Inc.Xtampza Er | $19 | $17,76715 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $183 | $17,53128 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 477 internal medicine providers in Delaware.
Other internal medicine in Wilmington
- Jose CastroWilmington$27K
- Marcia Gina CastroWilmington$24K
- Robert KopeckiWilmington$15K
- Franklin AmpaduWilmington$15K
- Andrew MyersWilmington$15K
- Armand DesanctisWilmington$11K
- Carol Alvarado-BarrantesWilmington$10K
- Terry HortonWilmington$5K
- Jerry GluckmanWilmington$5K
- Alina GoverWilmington$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.